Verso un modello integrato di sviluppo, approvazione e accesso dei farmaci per malattie rare in Europa
Enrico Costa(Brigham and Women's Hospital), Nicola Magrini(Azienda Unità Sanitaria Locale Della Romagna)
Cited by 1
Related Papers
Outrageous prices of orphan drugs: a call for collaboration
|The Lancet|2018|160
The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
|Orphanet Journal of Rare Diseases|2022|51
Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: Systematic review and meta-analysis
|Cancer Treatment Reviews|2015|45
Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (<scp>HASTE</scp>): How to meet major health needs at a reasonable cost
|American Journal of Hematology|2020|31
Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with severe COVD-19 related lung injury
|European Journal of Internal Medicine|2020|22